CIBC World Markets’s Pacira BioSciences PCRX Stock Holding History

CIBC World Markets’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,169	Closed	-$253K	–	1830
2025 Q1	$253K	Buy	+10,169	New	+$243K	﹤0.01%	1339

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

CIBC World Markets's PCRX Position: Q2 2025 in Review

CIBC World Markets sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 10,169 shares — an estimated $253K sold.

CIBC World Markets first reported a position in PCRX in Q1 2025 and held it in 1 quarter. The position peaked at $253K in Q1 2025. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

CIBC World Markets reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
CIBC World Markets sold 10,169 Pacira BioSciences shares in Q2 2025, an estimated $253K.
CIBC World Markets first reported a position in Pacira BioSciences in Q1 2025 and held it in 1 quarter.
CIBC World Markets's Pacira BioSciences position peaked at $253K in Q1 2025.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.